persevERA Breast Cancer Study Keeps Oral ER-Targeting Strategy in Focus Despite Negative Primary Result

At the 2026 ASCO Annual Meeting, one of the most closely watched breast cancer questions was whether an oral estrogen receptor antagonist and degrader could move into the first-line setting and improve outcomes when paired with a CDK4/6 inhibitor. The answer from the phase 3 persevERA breast cancer (BC) trial was not practice-changing, but it was still clinically meaningful.

The trial evaluated giredestrant plus palbociclib compared with letrozole plus palbociclib as first-line therapy for patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer. Giredestrant produced a numerical improvement in investigator-assessed progression-free survival, but the study did not meet its primary endpoint.

Median progression-free survival was 33.1 months with giredestrant plus palbociclib versus 28.2 months with letrozole plus palbociclib, a difference of 4.9 months. The hazard ratio was 0.89, with a 95% confidence interval of 0.76 to 1.05 and a p-value of 0.1553. Overall survival was not evaluable, and the OS hazard ratio was 1.03.

Dr. Komal L. Jhaveri, a breast medical oncologist at Memorial Sloan Kettering Cancer Center, describes the study as an important test of a strategy many in the field have been watching closely. The question, Dr. Jhaveri explains, was whether clinicians could replace the current standard approach — an aromatase inhibitor with a CDK4/6 inhibitor — with an oral ER-targeting agent plus a CDK4/6 inhibitor in the first-line endocrine-sensitive setting.

“The short answer is no, we’re not yet ready to switch that,” Dr. Jhaveri tells SurvivorNet Connect. “It was a negative study in that the study did not achieve statistical significance to change our practice tomorrow.”

Still, Dr. Jhaveri notes that the trial was not without a signal. “What we also learned was that there was in fact a numerical gain,” she says, pointing to the nearly 5-month median PFS difference favoring giredestrant plus palbociclib.

For oncologists, the key message is one of balance. The data do not support replacing aromatase inhibitor plus CDK4/6 inhibition as the first-line standard for endocrine-sensitive ER+ metastatic breast cancer. But the trial does add to an important biologic and clinical discussion about whether deeper ER targeting earlier in the disease course can delay endocrine resistance.

Study Design and Key Results

The study enrolled 992 patients with de novo metastatic breast cancer or recurrent locally advanced or metastatic disease who had not received prior systemic therapy for advanced disease. Patients were randomly assigned to giredestrant 30 mg daily plus palbociclib or letrozole 2.5 mg daily plus palbociclib. Premenopausal and perimenopausal women, as well as men, received a luteinizing hormone-releasing hormone agonist.

Secondary efficacy results were generally similar between the two arms.

• The objective response rate was 60.2% with giredestrant plus palbociclib and 58.8% with letrozole plus palbociclib.
• Clinical benefit rates were also nearly identical, at 82.6% and 82.1%, respectively.
• Median duration of response was 38.5 months with giredestrant compared with 30.4 months with letrozole, with a hazard ratio of 0.80 and a p-value of 0.056.

Safety did not reveal unexpected concerns. The most common grade 3 or 4 adverse events in the giredestrant arm were hematologic abnormalities associated with palbociclib. Endocrine therapy discontinuations due to adverse events were similar between groups, occurring in 6.5% of patients treated with giredestrant and 5.5% of those treated with letrozole.

Why ESR1 Resistance Still Matters

The biologic rationale behind persevERA BC centers on ESR1 mutations, one of the best-recognized mechanisms of endocrine resistance in ER+ metastatic breast cancer. These mutations can emerge under the selective pressure of aromatase inhibition and allow tumor growth to remain driven by the estrogen receptor pathway in a ligand-independent manner.

Dr. Jhaveri says the trial tested whether using an oral ER antagonist and degrader upfront, before resistance develops, could delay the emergence of ESR1 mutations and improve outcomes.

That question remains open. The primary endpoint was not met, and the confidence interval crossed 1. But Dr. Jhaveri points out that the Kaplan-Meier curves appeared to overlap early and separate later, after approximately 12 months.

It will be important to understand whether ESR1 mutation emergence or other resistance mechanisms help explain that pattern, she says.

Clinical Implications: No Immediate Practice Change, But More Questions Ahead

Clinically, persevERA BC does not alter the current first-line standard. For most patients with endocrine-sensitive ER+, HER2- metastatic breast cancer, endocrine therapy plus CDK4/6 inhibition remains the backbone of care. The trial also does not answer whether giredestrant may be more useful in a different population, with a different CDK4/6 inhibitor, or after endocrine resistance has already emerged.

That is why upcoming and ongoing studies remain important. The ASCO abstract notes that the pionERA BC trial is evaluating giredestrant versus fulvestrant, each combined with physician’s choice of CDK4/6 inhibitor, in patients who relapsed on adjuvant endocrine therapy or had a treatment-free interval shorter than 12 months.

Dr. Jhaveri also emphasized the need to watch other oral ER-targeting strategies and trials that may help clarify whether earlier intervention against ESR1-driven resistance can improve outcomes.

For now, persevERA BC should be read as a negative phase 3 trial with an informative signal. It does not justify a first-line practice change, but it keeps the field focused on a central question in ER+ metastatic breast cancer: not simply whether oral ER-targeting agents work, but when they should be used, in whom, and how they should be sequenced with the growing number of available targeted therapies.